Treatment of Ascaris lumbricoides Infection
For Ascaris lumbricoides infection, treat with a single dose of albendazole 400 mg, mebendazole 500 mg, or ivermectin 200 μg/kg—all three options are equally effective with cure rates exceeding 93%. 1
Standard Treatment Approach
The 2025 UK guidelines provide clear first-line options for ascariasis treatment 1:
- Albendazole 400 mg PO single dose
- Mebendazole 500 mg PO single dose
- Ivermectin 200 μg/kg PO single dose
These three regimens are therapeutically equivalent with no clinically meaningful differences in efficacy or safety. A Cochrane systematic review of 30 RCTs involving 6,442 participants confirmed parasitological cure rates of approximately 93-98% across all three drugs, with egg reduction rates of 96-100% 2. The evidence shows no superiority of any single agent over the others.
Special Populations
Children Under 2 Years
For children aged 12-24 months, the guidelines recommend discussing treatment with an expert before proceeding 1. The empirical treatment regimen (albendazole 400 mg plus ivermectin 200 μg/kg) is explicitly recommended only for those aged >24 months 1.
Pregnant Women
Pregnant women should be treated with pyrantel pamoate rather than albendazole or mebendazole 3, 4. This recommendation prioritizes fetal safety, as benzimidazoles (albendazole/mebendazole) have theoretical teratogenic concerns in the first trimester.
For pregnant women with biliary ascariasis—a serious complication more common in pregnancy—management becomes more complex 5:
- Conservative management (supportive care, monitoring) succeeds in approximately 60% of cases
- Endoscopic extraction with lead shielding of the fetus may be required in non-responsive cases (successful in ~67%)
- Surgical intervention carries risks of fetal wastage and premature labor and should be reserved for endoscopic failures
The study of 15 pregnant women with biliary ascariasis showed that 66.6% were in their third trimester, emphasizing the importance of routine deworming in women of childbearing age in endemic areas 5.
Clinical Context and Pitfalls
When to Treat
All patients with confirmed A. lumbricoides infection warrant treatment, even if asymptomatic, to prevent complications from worm migration including intestinal obstruction (especially in children), biliary obstruction, pancreatitis, and Löeffler syndrome 1, 4.
Diagnostic Confirmation
Diagnosis is established by:
- Concentrated stool microscopy (standard approach)
- Faecal PCR (higher sensitivity) 1
Key Complications to Monitor
- Intestinal obstruction (more common in children with heavy worm burdens)
- Biliary ascariasis (more common in adults, particularly pregnant women)
- Löeffler syndrome (acute pulmonary manifestations during larval migration)
- Malnutrition (especially in children with chronic infection)
Reinfection Risk
In endemic areas, reinfection commonly occurs within 6 months post-treatment 6. Risk factors for rapid reinfection include:
- Younger age (children most susceptible)
- Lower socioeconomic status
- Previous infection status
- Poor sanitation conditions
At 6 months post-treatment, cumulative reinfection incidence reaches 34.6%, rising to 52.6% by 15 months 6. This underscores that single-dose treatment, while highly effective for acute cure, does not provide lasting protection without addressing environmental factors.
Safety Profile
Adverse events are generally mild and similar across all three anthelmintics 2:
- Nausea, vomiting
- Abdominal pain
- Diarrhea
- Headache
- Fever
No serious adverse events or complications were reported in the comprehensive Cochrane review 2. The drugs are safe for treating both children and adults with confirmed infection.
Important Caveat for Ivermectin
Before treating with ivermectin, exclude Loa loa infection in people who have traveled to endemic regions (Central and West Africa) 1. Ivermectin can precipitate severe encephalopathy in patients with high Loa loa microfilaraemia.